Genovis MACD + Support, Resistance shows LONGgraph will tell you everything
Soon touching the support field where it have past history of pushing up, MACD indicates change aswell.
0.95SEK
61.50 MSEK
158.23 MSEK
55.62 M
About GENOVIS AB
Sector
Industry
CEO
Fredrik Olsson
Website
Headquarters
Lund
Employees (FY)
37
Founded
1999
ISIN
SE0002485979
FIGI
BBG001Y25KX9
Genovis AB engages in the research and development of enzyme products. Its product portfolio includes SmartEnzymes, which offers to pharmaceutical and medical device industries tools that facilitate the development of new treatment methods and diagnostics. The company was founded by Inga Sarah Maria Fredriksson in 1999 and is headquartered in Lund, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of GENO is 28.10 SEK — it has decreased by 1.75% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange GENOVIS AB stocks are traded under the ticker GENO.
GENOVIS AB is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
GENO stock is 5.47% volatile and has beta coefficient of 0.34. Check out the list of the most volatile stocks — is GENOVIS AB there?
One year price forecast for GENOVIS AB has a max estimate of 75.00 SEK and a min estimate of 48.00 SEK.
GENO earnings for the last quarter are 0.98 SEK per share, whereas the estimation was 0.86 SEK resulting in a 14.04% surprise. The estimated earnings for the next quarter are 0.32 SEK per share. See more details about GENOVIS AB earnings.
GENOVIS AB revenue for the last quarter amounts to 30.20 M SEK despite the estimated figure of 30.50 M SEK. In the next quarter revenue is expected to reach 32.60 M SEK.
Yes, you can track GENOVIS AB financials in yearly and quarterly reports right on TradingView.
GENO stock has fallen by 9.06% compared to the previous week, the month change is a 11.64% fall, over the last year GENOVIS AB has showed a 51.30% decrease.
GENO net income for the last quarter is −422.00 K SEK, while the quarter before that showed 3.14 M SEK of net income which accounts for −113.45% change. Track more GENOVIS AB financial stats to get the full picture.
Today GENOVIS AB has the market capitalization of 1.87 B, it has decreased by 2.41% over the last week.
No, GENO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GENO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENOVIS AB stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 20, 2024, the company has 37.00 employees. See our rating of the largest employees — is GENOVIS AB on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENOVIS AB technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENOVIS AB stock shows the sell signal. See more of GENOVIS AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on GENOVIS AB future price: according to them, GENO price has a max estimate of 75.00 SEK and a min estimate of 48.00 SEK. Read a more detailed GENOVIS AB forecast: see what analysts think of GENOVIS AB and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENOVIS AB EBITDA is 63.72 M SEK, and current EBITDA margin is 40.27%. See more stats in GENOVIS AB financial statements.